3.8 Review

Transmembrane mucins as novel therapeutic targets

Journal

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM
Volume 6, Issue 6, Pages 835-848

Publisher

ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
DOI: 10.1586/EEM.11.70

Keywords

cytokines; MUC1; MUC16; MUC4; nanomedicine; steroid hormones

Funding

  1. NIH [R01HD029963, P50CA098258, U54 CA151668]
  2. EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029963] Funding Source: NIH RePORTER
  3. NATIONAL CANCER INSTITUTE [P50CA098258, U54CA151668] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Membrane-tethered mucin glycoproteins are abundantly expressed at the apical surfaces of simple epithelia, where they play important roles in lubricating and protecting tissues from pathogens and enzymatic attack. Notable examples of these mucins are MUC1, MUC4 and MUC16 (also known as cancer antigen 125). In adenocarcinomas, apical mucin restriction is lost and overall expression is often highly increased. High-level mucin expression protects tumors from killing by the host immune system, as well as by chemotherapeutic agents, and affords protection from apoptosis. Mucin expression can increase as the result of gene duplication and/ or in response to hormones, cytokines and growth factors prevalent in the tumor milieu. Rises in the normally low levels of mucin fragments in serum have been used as markers of disease, such as tumor burden, for many years. Currently, several approaches are being examined that target mucins for immunization or nanomedicine using mucin-specific antibodies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available